home > drugs a-z list > cutivate lotion (fluticasone propionate lotion) drug center > cutivate lotion (fluticasone propionate lotion) drug - side effects and drug interactions

Recommended Topic Related To:

Cutivate Lotion

Allergy Drugs: Prescription and OTC »

Allergy medications overview

The arsenal of allergy drugs includes dozens of medications that relieve allergy symptoms when confronted with a trigger known as an allergen. That trigger could be something from a plant, such as pollen, or something from an animal (pet dander, dust mites, cockroaches). Other allergy triggers include certain fragrances or chemical substances.

What causes a person's allergic reaction is highly individual. But the reactions are often universal: swelling and inflammation, especially around the eyes, nose, and throat, usually accompanied by itching.

Some allergy medications work against the effects of histamines, which are released during an allergic reaction. Other medications reduce swelling, affect the immune system, or affect release of other substances associated with allergic reactions.

Many allergy drugs are available without a prescription.

For what conditions are allergy medicatio...

Read the Allergy Drugs: Prescription and OTC article »

Cutivate Lotion

font size

SIDE EFFECTS

Clinical Trial Experience

In 2 multicenter vehicle-controlled clinical trials of once-daily application of CUTIVATE® Lotion by 196 adult and 242 pediatric patients, the total incidence of adverse reactions considered drug related by investigators was approximately 4%. Events were local cutaneous events, usually mild and self-limiting, and consisted primarily of burning/stinging (2%). All other drug-related events occurred with an incidence of less than 1%, and inclusively were contact dermatitis, exacerbation of atopic dermatitis, folliculitis of legs, pruritus, pustules on arm, rash, and skin infection.

The incidence of drug-related events on drug compared to vehicle (4% and 5%, respectively) was similar. The incidence of drug-related events between study populations of 242 pediatric patients (age 3 months to < 17 years) and 196 adult patients (17 years or older) (4% and 5%, respectively) was also similar.

In an open-label study of 44 pediatric patients applying CUTIVATE® Lotion to at least 35% of body surface area twice daily for 3 or 4 weeks, the overall incidence of drug-related adverse events was 14%. Events were local, cutaneous, and inclusively were dry skin (7%), stinging at application site (5%), and excoriation (2%).

Table 2: Drug Related Adverse Events from Controlled Clinical Trials (n=438)

Adverse Events CUTIVATE® Lotion
N=221		 Vehicle
N=217
Burning/Stinging skin 4 (2%) 3 (1%)
Contact Dermatitis 0 1 ( < 1%)
Exacerbation of Atopic dermatitis 0 1 ( < 1%)
Folliculitis of legs 2 ( < 1%) 0
Irritant Contact Dermatitis 0 1 ( < 1%)
Pruritus 1 ( < 1%) 1 ( < 1%)
Pustules on Arms 1 ( < 1%) 0
Rash 1 ( < 1%) 2 ( < 1%)
Skin Infection 0 3 (1%)

Table 3: Drug Related Adverse Events From Pediatric Open Label Trial (n=44)

Adverse Events CUTIVATE® Lotion Twice Daily
Dry skin at multiple sites 3 (7%)
Stinging at Application Sites 2 (5%)
Excoriation 1 (2%)

The table below summarizes all adverse events by body system that occurred in at least 1% of patients in either the drug or vehicle group in controlled clinical trials.

Table 4: Adverse Events Occurring in ≥ 1% of Patients from Either Arm from Controlled Clinical Trials (n=438)

Body System CUTIVATE®Lotion
N = 221		 Vehicle Lotion
N = 217
Any Adverse Event 77 (35%) 82 (38%)
Skin
  Burning and Stinging 4 (2%) 3 (1%)
  Pruritus 3 (1%) 5 (2%)
  Rash 2 (<1%) 3 (1%)
  Skin Infection 0 3 (1%)
Ear, Nose, Throat
  Common Cold 9 (4%) 5 (2%)
  Ear Infection 3 (1%) 3 (1%)
  Nasal Sinus Infection 2 (<1%) 4 (2%)
  Rhinitis 1 (<1%) 3 (1%)
  Upper Respiratory Tract Infection 6 (3%) 7 (3%)
Gastrointestinal
  Normal Tooth Eruption 2 (< 1%) 3 (1%)
  Diarrhea 3 (1%) 0
  Vomiting 3 (1%) 2 (<1%)
Lower Respiratory
  Cough 7 (3%) 6 (3%)
  Influenza 5 (2%) 0
  Wheeze 0 3 (1%)
Neurology
  Headache 4 (2%) 5 (2%)
Non-Site Specific
  Fever 8 (4%) 8 (4%)
  Seasonal Allergy 2 ( < 1%) 3 (1%)

During the clinical trials, eczema herpeticum occurred in a 33-year-old male patient treated with CUTIVATE® Lotion. Additionally, a 4-month-old patient treated with CUTIVATE® Lotion in the open-label trial had marked elevations of the hepatic enzymes AST and ALT.

Post Marketing Experience

Systemic adverse events with CUTIVATE® Cream and CUTIVATE® Ointment have included: immunosuppression/Pneumocystis carinii pneumonia/leukopenia/thrombocytopenia; hyperglycemia/ glycosuria; Cushing syndrome; generalized body edema/blurred vision; and acute urticarial reaction (edema, urticaria, pruritus, and throat swelling).

The following localized adverse reactions have been reported during post approval use of CUTIVATE® Lotion: erythema, edema/swelling, bleeding, and a reported lack of efficacy.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

DRUG INTERACTIONS

No information provided.

Last reviewed on RxList: 6/16/2011
This monograph has been modified to include the generic and brand name in many instances.

Additional Cutivate Lotion Information

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Privacy Policy

Women's Health

Find out what women really need.


From WebMD

Skin Problems and Treatments Resources
Featured Centers
Health Solutions From Our Sponsors